{"id":55780,"date":"2023-04-13T14:03:40","date_gmt":"2023-04-13T12:03:40","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/twist-bioscience-launches-tcr-and-car-libraries-to-enable-the-development-of-cell-therapies\/"},"modified":"2023-04-13T14:03:40","modified_gmt":"2023-04-13T12:03:40","slug":"twist-bioscience-launches-tcr-and-car-libraries-to-enable-the-development-of-cell-therapies","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/twist-bioscience-launches-tcr-and-car-libraries-to-enable-the-development-of-cell-therapies\/","title":{"rendered":"Twist Bioscience Launches TCR and CAR Libraries to Enable the Development of Cell Therapies"},"content":{"rendered":"
\n

\nTCR and CAR libraries enable comprehensive screening of combinations of custom gene parts including domains from TCRs and CARs<\/i><\/p>\n

\nInformation about the offering available at AACR Annual Meeting 2023<\/i><\/p>\n

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Twist Bioscience Corporation<\/a> (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of Twist T-cell Receptor (TCR), and Twist chimeric antigen receptor (CAR) Libraries<\/a>. These new libraries provide researchers with the ability to rapidly create custom libraries that can enable the identification and development of next generation cell therapies.<\/p>\n

<\/a><\/p>\n

\n\u201cWith the dramatic increase in interest around cell and gene therapies, the addition of Twist CAR and TCR Libraries offers an important and differentiated tool to enable the development of the next generation of treatments for those suffering from a wide range of diseases,\u201d said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. \u201cTwist CAR and TCR Libraries allow researchers and drug developers to fine tune these receptors to address the challenges of cell therapies, including off-target toxicity, enabling rapid advancement toward the clinic.\u201d<\/p>\n

\nTwist TCR and CAR Libraries are large and diverse libraries made of up to 10,000 gene fragment combinations. This exceptional diversity enables high-throughput screening and characterization of novel and known sequence variants for therapeutic discovery. In these libraries, combinations of custom gene parts are shuffled to allow customers to test multiple elements at once, explore new combinations of variable binding regions and select candidates with the greatest therapeutic potential, accelerating the discovery phase and expediting the timeline to the clinic.<\/p>\n

\n\u201cWhile cell therapies have made a meaningful impact clinically, they have not yet reached their full potential,\u201d said Colin Farlow, CEO & Cofounder of Serotiny. \u201cWe partnered with Twist to accelerate progress toward our goal of engineering the next generation of cell therapies. Twist built CAR libraries of exceptional size and complexity that Serotiny utilized to discover synthetic receptors, aiming to decrease the costs and increase the effectiveness of cell therapies targeting solid tumors.\u201d<\/p>\n

\nTwist TCR and CAR Libraries Production Workflow<\/b><\/p>\n

\nTwist designs variations of customer selected DNA sequences. The sequences then go through the assembly process where custom gene parts are \u201cshuffled.\u201d In TCR libraries, the alpha and beta chains are shuffled to create precise user-defined alpha and beta pairs or they can be shuffled into combinatorial pairs. In CAR libraries, variants of each domain are shuffled in a process called scaffold optimization. The variants are then cloned and sequenced. Before shipping to the customer, Twist uses next-generation sequencing to verify the entire library.<\/p>\n

\nPresence at the American Association for Cancer Research (AACR) Annual Meeting 2023<\/b><\/p>\n

\nInformation about the Twist TCR and CAR Libraries will be available at the Twist booth at the AACR Annual Meeting 2023, taking place April 14-19 in Orlando, Florida.<\/p>\n

\nIn addition, Twist will present the following posters at the conference:<\/p>\n